Transcriptional control of the tumor- and hypoxia-marker carbonic anhydrase 9: A one transcription factor (HIF-1) show?

Biochimica et Biophysica Acta - Reviews on Cancer

Volumn 1795, Issue 2, 2009, Pages 162-172

  Kaluz, Stefan ^a   Kaluzová, Milota ^a   Liao, Shu Yuan ^a   Lerman, Michael ^b   Stanbridge, Eric J ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Carbonic anhydrase IX; Hypoxia; Hypoxia inducible factor; Transcriptional regulation

Indexed keywords

CARBONATE DEHYDRATASE IX; HYPOXIA INDUCIBLE FACTOR 1; TUMOR MARKER;

CA 9 GENE; CANCER DIAGNOSIS; CANCER RESEARCH; GENE ACTIVATION; GENE EXPRESSION; HUMAN; HYPOXIA; NONHUMAN; PRIORITY JOURNAL; PROGNOSIS; PROMOTER REGION; REVIEW; SOLID TUMOR; TRANSCRIPTION INITIATION; TRANSCRIPTION REGULATION; TUMOR GENE;

ANTIGENS, NEOPLASM; BASE SEQUENCE; BIOLOGICAL MARKERS; CARBONIC ANHYDRASES; CELL HYPOXIA; EPIGENESIS, GENETIC; GENE EXPRESSION REGULATION, ENZYMOLOGIC; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1; MOLECULAR SEQUENCE DATA; NEOPLASMS; PROMOTER REGIONS, GENETIC; RESPONSE ELEMENTS; TRANSCRIPTION, GENETIC; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEIN P53;

EID: 62749124795     PISSN: 0304419X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bbcan.2009.01.001     Document Type: Review

References (84)

1. Brown J.M. Exploiting the hypoxic cancer cell: mechanisms and therapeutic strategies. Molecular Medicine Today 6 4 (2000) 157-162
2. Liao S.Y., et al. Identification of the Mn antigen as a diagnostic biomarker of cervical intraepithelial squamous and glandular neoplasia and cervical carcinomas. Am. J. Pathol. 145 3 (1994) 598-609
3. Liao S.Y., et al. Identification of the MN/CA9 protein as a reliable diagnostic biomarker of clear cell carcinoma of the kidney. Cancer Res. 57 14 (1997) 2827-2831
4. Chia S.K., et al. Prognostic significance of a novel hypoxia-regulated marker, carbonic anhydrase IX, in invasive breast carcinoma. J. Clin. Oncol. 19 16 (2001) 3660-3668
5. Beasley N.J.P., et al. Carbonic anhydrase IX, an endogenous hypoxia marker, expression in head and neck squamous cell carcinoma and its relationship to hypoxia, necrosis, and microvessel density. Cancer Res. 61 13 (2001) 5262-5267
6. Giatromanolaki A., et al. Expression of hypoxia-inducible carbonic anhydrase-9 relates to angiogenic pathways and independently to poor outcome in non-small cell lung cancer. Cancer Res. 61 21 (2001) 7992-7998
7. Proescholdt M.A., et al. Expression of hypoxia-inducible carbonic anhydrases in brain tumors. Neuro-Oncology 7 4 (2005) 465-475
8. Haapasalo J.A., et al. Expression of carbonic anhydrase IX in astrocytic tumors predicts poor prognosis. Clin. Cancer Res. 12 2 (2006) 473-477
9. Maseide K., et al. Carbonic anhydrase IX as a marker for poor prognosis in soft tissue sarcoma. Clin. Cancer Res. 10 13 (2004) 4464-4471
10. Loncaster J.A., et al. Carbonic anhydrase (CA IX) expression, a potential new intrinsic marker of hypoxia: correlations with tumor oxygen measurements and prognosis in locally advanced carcinoma of the cervix. Cancer Res. 61 17 (2001) 6394-6399
11. Jonathan R.A., et al. The prognostic value of endogenous hypoxia-related markers for head and neck squamous cell carcinomas treated with ARCON. Radiother. Oncol. 79 3 (2006) 288-297
12. Bui M.H.T., et al. Carbonic anhydrase IX is an independent predictor of survival in advanced renal clear cell carcinoma: implications for prognosis and therapy. Clin. Cancer Res. 9 2 (2003) 802-811
13. Wykoff C.C., et al. Hypoxia-inducible expression of tumor-associated carbonic anhydrases. Cancer Res. 60 24 (2000) 7075-7083
14. Olive P.L., et al. Carbonic anhydrase 9 as an endogenous marker for hypoxic cells in cervical cancer. Cancer Res. 61 24 (2001) 8924-8929
15. Liao, S., M. Lerman, and E. Stanbridge, Expression of transmembrane carbonic anhydrases, CAIX and CAXII, in human development. Submitted.
16. Mayer A., Hockel M., and Vaupel P. Carbonic anhydrase IX expression and tumor oxygenation status do not correlate at the microregional level in locally-advanced cancers of the uterine cervix. Clin. Cancer Res. 11 20 (2005) 7220-7225
17. Ivanov S., et al. Expression of hypoxia-inducible cell-surface transmembrane carbonic anhydrases in human cancer. Am. J. Pathol. 158 3 (2001) 905-919
18. Surfus J.E., et al. Anti-renal-cell carcinoma chimeric antibody G250 facilitates antibody-dependent cellular cytotoxicity with in vitro and in vivo interleukin-2-activated effectors. J. Immunother. 19 3 (1996) 184-191
19. Bleumer I., et al. A phase II trial of chimeric monoclonal antibody G250 for advanced renal cell carcinoma patients. British J. Cancer 90 5 (2004) 985-990
20. Vince J.W., and Reithmeier R.A.F. Carbonic anhydrase II binds to the carboxyl terminus of human band 3, the erythrocyte Cl-/HCO3- exchanger. J. Biol. Chem. 273 43 (1998) 28430-28437
21. Pastorekova S., Parkkila S., and Zavada J. Tumor-associated carbonic anhydrases and their clinical significance. Adv. Clin. Chem. Vol 42 42 (2006) 167-216
22. Parkkila S. Significance of pH regulation and carbonic anhydrases in tumour progression and implications for diagnostic and therapeutic approaches. Bju Int. 101 (2008) 16-21
23. Shuch B., Li Z.H., and Belldegrun A.S. Carbonic anhydrase IX and renal cell carcinoma: prognosis, response to systemic therapy, and future vaccine strategies. Bju Int. 101 (2008) 25-30
24. Opavsky R., et al. Human MN/CA9 gene, a novel member of the carbonic anhydrase family: structure and exon to protein domain relationships. Genomics 33 3 (1996) 480-487
25. Nakagawa Y., et al. Radiation hybrid mapping of the human MN/CA9 locus to chromosome band 9p12-p13. Genomics 53 1 (1998) 118-119
26. Pastorek J., et al. Cloning and characterization of Mn, a human tumor-associated protein with a domain homologous to carbonic-anhydrase and a putative helix-loop-helix DNA-binding segment. Oncogene 9 10 (1994) 2877-2888
27. Pastorekova S., et al. Carbonic anhydrase IX, MN/CA IX: analysis of stomach complementary DNA sequence and expression in human and rat alimentary tracts. Gastroenterology 112 2 (1997) 398-408
28. Barathova M., et al. Alternative splicing variant of the hypoxia marker carbonic anhydrase IX expressed independently of hypoxia and tumour phenotype. British J. Cancer 98 (2008) 129-136
29. Grabmaier K., et al. Strict regulation of CAIX(G250/MN) by HIF-1 alpha in clear cell renal cell carcinoma. Oncogene 23 33 (2004) 5624-5631
30. Kaluz S., et al. Transcriptional regulation of the MN/CA 9 gene coding for the tumor-associated carbonic anhydrase IX - identification and characterization of a proximal silencer element. J. Biol. Chem. 274 46 (1999) 32588-32595
31. Kaluz S., Kaluzova M., and Stanbridge E.J. Rational design of minimal hypoxia-inducible enhancers. Biochemical And Biophysical Research Communications 370 4 (2008) 613-618
32. Kaluz S., Kaluzova M., and Stanbridge E.J. Expression of the hypoxia marker carbonic anhydrase IX is critically dependent on SP1 activity. Identification of a novel type of hypoxia-responsive enhancer. Cancer Res. 63 5 (2003) 917-922
33. Ivanov S.V., et al. Down-regulation of transmembrane carbonic anhydrases in renal cell carcinoma cell lines by wild-type von Hippel-Lindau transgenes. Proc. Natl. Acad. Sci. U. S. A. 95 21 (1998) 12596-12601
34. Kaluzova M., et al. Characterization of the MN/CA 9 promoter proximal region: a role for specificity protein (SP) and activator protein 1 (AP1) factors. Biochem. J. 359 (2001) 669-677
35. Black A.R., Black J.D., and Azizkhan-Clifford J. Sp1 and Kruppel-like factor family of transcription factors in cell growth regulation and cancer. J. Cell. Physiol. 188 2 (2001) 143-160
36. Kopacek J., et al. MAPK pathway contributes to density- and hypoxia-induced expression of the tumor-associated carbonic anhydrase IX. Biochim. Biophys. Acta-Gene Struc. Expr. 1729 1 (2005) 41-49
37. Sanchez-Elsner T., et al. Endoglin expression is regulated by transcriptional cooperation between the hypoxia and transforming growth factor-beta pathways. J. Biol. Chem. 277 46 (2002) 43799-43808
38. Miki N., Ikuta M., and Matsui T. Hypoxia-induced activation of the retinoic acid receptor-related orphan receptor alpha 4 gene by an interaction between hypoxia-inducible factor-1 and Sp1. J. Biol. Chem. 279 15 (2004) 15025-15031
39. Bae S.K., et al. Hypoxic induction of human visfatin gene is directly mediated by hypoxia-inducible factor-1. FEBS Lett. 580 17 (2006) 4105-4113
40. Laderoute K.R. The interaction between HIF-1 and AP-1 transcription factors in response to low oxygen. Semin. Cell Dev. Biol. 16 4-5 (2005) 502-513
41. Michiels C., et al. HIF-1 and AP-1 cooperate to increase gene expression in hypoxia: role of MAP kinases. Iubmb Life 52 1-2 (2001) 49-53
42. Stanbridge E.J., et al. Human cell hybrids - analysis of transformation and tumorigenicity. Science 215 4530 (1982) 252-259
43. Cho M., et al. Hypomethylation of the MN/CA9 promoter and upregulated MN/CA9 expression in human renal cell carcinoma. British J. Cancer 85 4 (2001) 563-567
44. Cho M., et al. Activation of the MN/CA9 gene is associated with hypomethylation carcinoma cell lines. Mol. Carcinogen. 27 3 (2000) 184-189
45. Ashida S., et al. Effects of von Hippel-Lindau gene mutation and methylation status on expression of transmembrane carbonic anhydrases in renal cell carcinoma. J. Cancer Res. Clin. Oncol. 128 10 (2002) 561-568
46. Grabmaier K., et al. Renal cell carcinoma-associated G250 methylation and expression: in vivo and in vitro studies. Urology 60 2 (2002) 357-362
47. Kaluzova M., et al. DNA damage is a prerequisite for p53-mediated proteasomal degradation of HIF-1 alpha in hypoxic cells and downregulation of the hypoxia marker carbonic anhydrase IX. Mol. Cell. Biol. 24 13 (2004) 5757-5766
48. Jakubickova L., et al. Methylation of the CA9 promoter can modulate expression of the tumor-associated carbonic anhydrase IX in dense carcinoma cell lines. Int. J. Oncol. 26 4 (2005) 1121-1127
49. Huang L.E., and Bunn H.F. Hypoxia-inducible factor and its biomedical relevance. J. Biol. Chem. 278 22 (2003) 19575-19578
50. Schofield C.J., and Ratcliffe P.J. Signalling hypoxia by HIF hydroxylases. Biochem. Biophys. Res. Commun. 338 1 (2005) 617-626
51. Kaluz S., Kaluzova M., and Stanbridge E.J. Proteasomal inhibition attenuates transcriptional activity of hypoxia-inducible factor 1 (HIF-1) via specific effect on the HIF-1 alpha C-terminal activation domain. Mol. Cell. Biol. 26 15 (2006) 5895-5907
52. Kondo K., and Kaelin W.G. The von Hippel-Lindau tumor suppressor gene. Exp. Cell Res. 264 1 (2001) 117-125
53. Kaluz S., et al. Lowered oxygen tension induces expression of the hypoxia marker MN/carbonic anhydrase IX in the absence of hypoxia-inducible factor 1 alpha stabilization: a role for phosphatidylinositol 3′-kinase. Cancer Res. 62 15 (2002) 4469-4477
54. Hedley D., et al. Carbonic anhydrase IX expression, hypoxia, and prognosis in patients with uterine cervical carcinomas. Clin. Cancer Res. 9 15 (2003) 5666-5674
55. Brown J.M., and William W.R. Exploiting tumour hypoxia in cancer treatment. Nat. Rev. Cancer 4 6 (2004) 437-447
56. Dewhirst M.W., Cao Y., and Moeller B. Cycling hypoxia and free radicals regulate angiogenesis and radiotherapy response. Nat. Rev. Cancer 8 8 (2008) 425
57. Koritzinsky M., et al. Gene expression during acute and prolonged hypoxia is regulated by distinct mechanisms of translational control. EMBO J. 25 5 (2006) 1114-1125
58. Bristow R.G., and Hill R.P. Hypoxia, DNA repair and genetic instability. Nat. Rev. Cancer 8 3 (2008) 180-192
59. Bardos J.I., and Athcroft M. Hypoxia-inducible factor-1 and oncogenic signalling. BioEssays 26 3 (2004) 262-269
60. Koivunen P., et al. Catalytic properties of the asparaginyl hydroxylase (FIH) in the oxygen sensing pathway are distinct from those of its prolyl 4-hydroxylases. J. Biol. Chem. 279 11 (2004) 9899-9904
61. Ehrismann D., et al. Studies on the activity of the hypoxia-inducible-factor hydroxylases using an oxygen consumption assay. Biochem. J. 401 (2007) 227-234
62. Lisy K., and Peet D.J. Turn me on: regulating HIF transcriptional activity. Cell Death Differ. 15 4 (2008) 642-649
63. Zhong H., et al. Modulation of hypoxia-inducible factor 1 alpha expression by the epidermal growth factor/phosphatidylinositol 3-kinase/PTEN/AKT/FRAP pathway in human prostate cancer cells: implications for tumor angiogenesis and therapeutics. Cancer Res. 60 6 (2000) 1541-1545
64. Birle D.C., and Hedley D.W. Suppression of the hypoxia-inducible factor-1 response in cervical carcinoma xenografts by proteasome inhibitors. Cancer Res. 67 4 (2007) 1735-1743
65. Mayer A., et al. Lack of hypoxic response in uterine leiomyomas despite severe tissue hypoxia. Cancer Res. 68 12 (2008) 4719-4726
66. Raval R.R., et al. Contrasting properties of hypoxia-inducible factor 1 (HIF-1) and HIF-2 in von Hippel-Lindau-associated renal cell carcinoma. Mol. Cell. Biol. 25 13 (2005) 5675-5686
67. Lau K.W., et al. Target gene selectivity of hypoxia-inducible factor-alpha in renal cancer cells is conveyed by post-DNA-binding mechanisms. British J. Cancer 96 8 (2007) 1284-1292
68. Hu C.J., et al. The N-terminal transactivation domain confers target gene specificity of hypoxia-inducible factors HIF-1 alpha and HIF-2 alpha. Mol. Biol. Cell 18 (2007) 4528-4542
69. Dayan F., et al. The oxygen sensor factor-inhibiting hypoxia-inducible factor-1 controls expression of distinct genes through the bifunctional transcriptional character of hypoxia-inducible factor-alpha. Cancer Res. 66 7 (2006) 3688-3698
70. Ihnatko R., et al. Extracellular acidosis elevates carbonic anhydrase IX in human glioblastoma cells via transcriptional modulation that does not depend on hypoxia. Int> J. Oncol. 29 4 (2006) 1025-1032
71. Rafajova M., et al. Induction by hypoxia combined with low glucose or low bicarbonate and high posttranslational stability upon reoxygenation contribute to carbonic anhydrase IX expression in cancer cells. Int. J. Oncol. 24 4 (2004) 995-1004
72. Vordermark D., et al. Characterization of carbonic anhydrase IX (CA IX) as an endogenous marker of chronic hypoxia in live human tumor cells. International Journal Of Radiation Oncol. Biol. Phys. 61 4 (2005) 1197-1207
73. Mukhopadhyay D., et al. The von Hippel-Lindau tumor suppressor gene product interacts with Sp1 to repress vascular endothelial growth factor promoter activity. Mol. Cell. Biol. 17 9 (1997) 5629-5639
74. Rafty L.A., and Khachigian L.M. Von Hippel-Lindau tumor suppressor protein represses platelet-derived growth factor B-chain gene expression via the Sp1 binding element in the proximal PDGF-B promoter. J. Cell. Biochem. 85 3 (2002) 490-495
75. Blagosklonny M.V., et al. p53 inhibits hypoxia-inducible factor-stimulated transcription. J. Biol. Chem. 273 20 (1998) 11995-11998
76. Kaluz S., Kaluzova M., and Stanbridge E.J. The role of extracellular signal-regulated protein kinase in transcriptional regulation of the hypoxia marker carbonic anhydrase IX. J. Cell. Biochem. 97 1 (2006) 207-216
77. Romerio F., Riva A., and Zella D. Interferon-alpha 2b reduces phosphorylation and activity of MEK and ERK through a Ras/Raf-independent mechanism. British J. Cancer 83 4 (2000) 532-538
78. Brouwers A.H., et al. Interferons can upregulate the expression of the tumor associated antigen G250-MN/CA IX, a potential target for (radio)immunotherapy of renal cell carcinoma. Cancer Biother. Radiopharmaceutic. 18 4 (2003) 539-547
79. Sang N.L., et al. MAPK signaling up-regulates the activity of hypoxia-inducible factors by its effects on p300. J. Biol. Chem. 278 16 (2003) 14013-14019
80. Gut M.O., et al. Gastric hyperplasia in mice with targeted disruption of the carbonic anhydrase gene Car9. Gastroenterology 123 6 (2002) 1889-1903
81. Storci G., et al. The basal-like breast carcinoma phenotype is regulated by SLUG gene expression. J. Pathol. 214 1 (2008) 25-37
82. Zhang W.W. Development and application of adenoviral vectors for gene therapy of cancer. Cancer Gene Ther. 6 2 (1999) 113-138
83. Lim H.Y., et al. Tumor-specific gene therapy for uterine cervical cancer using MN/CA9-directed replication-competent adenovirus. Cancer Gene Ther. 11 8 (2004) 532-538
84. Divgi C. The use of positron-emission tomography in the diagnosis of tumour phenotype. Bju Int. 101 (2008) 36-38